Genetika%20prim - PowerPoint PPT Presentation

About This Presentation
Title:

Genetika%20prim

Description:

MGMT status v glioblast moch. INI1 prote n v rabdoidn ch tumoroch. Oligodendrogli my a ... MLPA (multiplex ligation-dependent probe amplification komercn kity) 1p ... – PowerPoint PPT presentation

Number of Views:130
Avg rating:3.0/5.0
Slides: 29
Provided by: Bor465
Category:

less

Transcript and Presenter's Notes

Title: Genetika%20prim


1
  • Genetika primárnych mozgových nádorov.

2
  • 1p / 19q status v oligodendrogliómoch
  • MGMT status v glioblastómoch
  • INI1 proteín v rabdoidných tumoroch

3
Oligodendrogliómy a 1p / 19q LOH.
T1W
4
Oligodendrogliómy
  • odpoved na PCV (1980, Levin et al.)
  • súvis s 1p / 19q (1994, Reifenberg et al.)

5
Metodiky
  • RFLP (restriction fragment length polymorphism)
  • PCR based microsatellite analysis
  • FISH
  • Quantitative PCR
  • CGH (comparative genomic hybridisation)
  • MLPA (multiplex ligation-dependent probe
    amplification komercné kity)

6
1p
strata 1p/19q v priebehu ochorenia strata
chemosenzitivity
  • Washington University od 1999
  • Kramáre leto 2006

7
Dopad na liecbu?
  • 1p / 19q negat, LOH 10q, PTEN mutácia, EGFR
    amplifikácia PCV terapia sa neodporúca (Ino et
    al.)

8
Morfológia
astro - like
oligo - like
9
MGMT a multiformný glioblastóm
10
(No Transcript)
11
  • MGMT gén na chromozóme 10q26
  • metylácia MGMT promótera epigenetický
    silencing

12
Metodiky
  • IHC
  • HPLC (high-performance liquid chromatography)
  • MSP (metylation sensitive PCR) aj s parafínu,
    ale presnejšie z kryo

13
(No Transcript)
14
Dopad na kliniku
  • benefit alkylacnej chemoterapie len u tumorov s
    metylovaným (silenced) promóterom pre MGMT
  • neexistuje alternatíva liecby !!!

15
(No Transcript)
16
  • vyÅ¡Å¡ie dávky temozolomidu?

17
Atypical teratoid / rhabdoid tumor - expresia
proteínu INI1
18
Atypical teratoid / rhabdoid tumour (AT/RT)
  • agresívny embryonálny CNS tumor
  • pôvodne popísaný ako agresívny variant Wilmsovho
    tumoru s rabdomyosarkomatóznymi crtami

19
  • hSNF5/INI1 gén lokalizovaný na 22q11.2
    supresorový gén pre AT/RT aj periférne rabdoidy
  • hSNF5/INI1 kóduje INI1 proteín z rodiny chromatín
    remodulujúceho komplexu (SWI/SFN) regulácia
    transkripcie génov
  • AT/RT rabdoidné elementy nemusia byt vyjadrené,
    imunofenotyp vysoko variabilný

20
(No Transcript)
21
INI1 proteín
  • komercne dostupná protilátka od 2004
  • silná korelácia molekulárnych cytogenetických a
    imunohistochemických znakov
  • AT/RT zablokovanie expresie
  • ostatné CNS tumory zachovaná expresia

22
(No Transcript)
23
Meduloblastóm
24
  • Biegel JA, Kalpana G, Knudsen ES, et al. The
    role of INI1 and the SWI/SNF complex in the
    development of rhabdoid tumors meeting summary
    from the workshop on childhood atypical
    teratoid/rhabdoid tumors. Cancer Res 2002,
    62323-8

Diagnóza AT / RT
  1. tumor má charakteristické morfologické a
    imunohistochemické crty AT/RT bez dokázanej
    mutácie INI1
  2. crty meduloblastóm / PNET s dokázanou INI 1
    mutáciou

25
  • SMARCB1/INI1 missense mutation in mucinous
    carcinoma with rhabdoid features Yong Mee Cho
    Jene Choi Ok-Jun Lee Hyang-Im Lee Duck Jong Han
    and Jae Y. Ro, pages 702706, Pathology
    International, Volume 56 Issue 11 Page 702-706,
    November 2006

26
52. Loss of INI1 Expression Is Characteristic of
Both Conventional and Proximal -Type Epithelioid
Sarcoma JL Hornick, P Dal Cm, COM Fletcher.
Brigham and Women's Hospital. Harvard Medical
School. Boston, MA.
27
Záver
  • microarray gene profilings are demonstrating that
    genetically-based prognosis may be more reliable
    than histologically-based prognosis (Nutt et al.,
    2003)

28
Použitá literatúra
  • 7th Congress of the European Association for
    Neurooncology (EANO), Postgraduate Course
    Biomarkers and Therapy in Neurooncology,
    University Campus, Court 2, Lecture Hall CI,
    Spitalgasse 2, 1090 Vienna, Austria Thursday,
    September 14, 2006, 9.00-10.30
  • MGMT Gene Silencing and Benefit from Temozolomide
    in Glioblastoma, Monika E. Hegi, Ph.D.,
    Annie-Claire Diserens, M.Sc., Thierry Gorlia,
    M.Sc., N Engl J Med 35210, march 10, 2005
  • Allelic Losses at 1p36 and 19q13 in Gliomas
    Correlation with Histologic Classification,
    Definition of a 150-kb Minimal Deleted Region on
    1p36, and Evaluation of CAMTA1 as a Candidate
    Tumor Suppressor Gene, Violetta Barbashina,1
    Paulo Salazar, Eric C. Holland, Marc K. Rosenblum
    and Marc Ladanyi, Clinical Cancer Research, Vol.
    11, 1119 1128, February 1, 2005
  • Alterations of the hSNF5/INI1 Gene in Central
    Nervous System Atypical Teratoid/Rhabdoid Tumors
    and Renal and Extrarenal Rhabdoid Tumors, Jaclyn
    A. Biegel,2 Lu Tan, Fan Zhang,
  • Luanne Wainwright, Pierre Russo, and Lucy B.
    Rorke, Clinical Cancer Research, Vol. 8,
    34613467, November 2002
Write a Comment
User Comments (0)
About PowerShow.com